Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Traws Pharma (TRAW) Shares Outstanding (2016 - 2025)

Traws Pharma (TRAW) has disclosed Shares Outstanding for 14 consecutive years, with $6737.0 as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding fell 99.82% year-over-year to $6737.0; the TTM value through Dec 2025 reached $6737.0, down 99.82%, while the annual FY2025 figure was $6737.0, 99.82% down from the prior year.
  • Shares Outstanding hit $9.1 million in Q4 2025 for Traws Pharma, up from $6737.0 in the prior quarter.
  • Across five years, Shares Outstanding topped out at $21.0 million in Q1 2023 and bottomed at $6737.0 in Q3 2025.
  • Average Shares Outstanding over 5 years is $9.3 million, with a median of $5.4 million recorded in 2024.
  • On a YoY basis, Shares Outstanding climbed as much as 598.27% in 2025 and fell as far as 99.82% in 2025.
  • Traws Pharma's Shares Outstanding stood at $20.9 million in 2021, then plummeted by 95.99% to $837040.0 in 2022, then increased by 0.38% to $840251.0 in 2023, then soared by 334.48% to $3.7 million in 2024, then tumbled by 99.82% to $6737.0 in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $6737.0, $7.1 million, and $7.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.